The mortality rate associated with STEMI has plateaued over the last decade1.
Up to 28% of patients develop heart failure 90-days post-Acute MI despite best practice PCI2.
The mortality rate associated with STEMI has plateaued over the last decade1.
Up to 28% of patients develop heart failure 90-days post-Acute MI despite best practice PCI2.
Reduction matters. Most.
Infarct size is strongly associated with subsequent mortality, heart failure and hospitalizations following Acute MI.
PiCSO clinical studies have demonstrated significant reduction in infarct size.
Superior results in STEMI patients with TIMI 0/16
This subpopulation has shown even stronger results when compared to a reference group:
References
PiCSO therapy
Intends to reduce infarct size by intermittent coronary sinus occlusion during PCI.
Aims to redistribute blood flow to damaged areas in patients with Acute MI.
Minimize risk in an urgent situation
Potential substantial cost savings
Revolutionizes the current standard of care, leading to improvement in quality of life, and reduction in health care cost at one year.
PiCSO therapy workflow
No delay in door-to-balloon time
PiCSO aims at clearing the microcirculation to salvage and detoxify myocardium
Intermittent coronary sinus occlusion temporarily increases pressure which may lead to:
Unique mode of action
addresses both ischemic and reperfusion injury